Logo Image
News|Articles|October 1, 2026

EADV 2026: Tilrekimig Achieves EASI-75 Across All Doses in Atopic Dermatitis

Fact checked by: Victoria Johnson
Listen
0:00 / 0:00

Key Takeaways

  • Trispecific blockade of upstream TSLP plus IL-4/IL-13 aims to broaden type 2 inflammatory pathway suppression and potentially enhance durability versus single-target cytokine inhibition.
  • EASI-75 at week 16 significantly favored tilrekimig versus placebo: 62.5% vs 19.9% (450 mg q2w) and 47.8%–61.0% vs 9.1% (50–400 mg q4w).
SHOW MORE

Tilrekimig, a trispecific IL-4/IL-13/TSLP antibody, met its EASI-75 primary endpoint at all doses in a phase 2 atopic dermatitis trial.

Tilrekimig (PF-07275315), an investigational trispecific antibody targeting interleukin-4 (IL-4), IL-13, and thymic stromal lymphopoietin (TSLP), met its primary endpoint of at least 75% improvement in Eczema Area and Severity Index (EASI-75) at week 16 across all evaluated doses versus placebo in adults with moderate to severe atopic dermatitis, according to phase 2 data Pfizer presented at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna, Austria.1

By blocking TSLP alongside its downstream effectors IL-4 and IL-13, tilrekimig is designed to provide broader coverage of type 2 inflammatory pathways and potentially more durable responses.1 The antibody has a half-life of about 37 days, which is expected to support monthly dosing. Tilrekimig joins other next-generation atopic dermatitis biologics presented at EADV 2026, including the half-life-extended IL-13 antibody zumilokibart.2

"The Week 16 results presented today are meaningful at this stage of development, with tilrekimig's tolerability profile supporting continued study in a larger patient population," said Eric Simpson, MD, MCR, of the Department of Dermatology at Oregon Health & Science University in Portland.

Frequently Asked Questions:

  • What is tilrekimig?
    Tilrekimig (PF-07275315) is an investigational trispecific antibody from Pfizer, which simultaneously binds IL-4, IL-13, and TSLP to block multiple drivers of type 2 inflammation. It has not been approved by any regulatory authority.
  • How often is tilrekimig dosed?
    With a half-life of about 37 days, tilrekimig is designed for monthly administration. Stage 2 of the phase 2 trial evaluated doses of 50 mg to 400 mg every 4 weeks.
  • What did the tilrekimig phase 2 trial show?
    At week 16, 47.8% to 62.5% of patients receiving tilrekimig achieved EASI-75 versus 9.1% to 19.9% with placebo, meeting the primary endpoint across all doses.

Tilrekimig Phase 2 EASI-75 and vIGA Results

The ongoing randomized, double-blind, placebo-controlled phase 2 trial is evaluating adults with moderate to severe atopic dermatitis.1 Data presented at EADV covered the first 2 stages of the study, both of which enrolled biologic-naive patients. Stage 1 evaluated subcutaneous tilrekimig 450 mg every 2 weeks versus placebo, while stage 2 tested tilrekimig 400 mg, 200 mg, or 50 mg every 4 weeks versus placebo.1

In stage 1, 62.5% of patients receiving tilrekimig 450 mg every 2 weeks achieved EASI-75 at week 16 compared with 19.9% receiving placebo (P = .0008). In stage 2, EASI-75 response rates were 58.5%, 61.0%, and 47.8% with the 400 mg, 200 mg, and 50 mg monthly doses, respectively, versus 9.1% with placebo (all P < .003).1

For the key secondary endpoint of a validated Investigator Global Assessment (vIGA) score of 0/1 with at least a 2-point improvement, 30.3% of stage 1 patients achieved response with tilrekimig versus 11.8% with placebo (P = .0251).1 Across the stage 2 monthly dosing groups, 26% to 27% of patients achieved vIGA 0/1 compared with 0% with placebo (all P < .006).1

Tilrekimig Itch Response, Safety, and Phase 3 Program

In an exploratory analysis, more patients receiving tilrekimig achieved a 4-point or greater reduction in weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) scores than those receiving placebo. Response rates were 42.5% with the 400 mg monthly dose and 50.8% with the 200 mg monthly dose, compared with 7.2% with placebo.1

According to results, tilrekimig was well tolerated, with no dose-dependent safety signals and no serious adverse events related to treatment in either stage.

Treatment-emergent adverse events occurred in 46.7% of patients receiving 450 mg every 2 weeks versus 28.9% with placebo in stage 1, and in 42.2% to 47.8% of patients across the stage 2 tilrekimig groups versus 52.2% with placebo. At doses up to 400 mg monthly, rates of conjunctivitis and injection-site reactions were comparable to placebo and lower than rates reported with IL-4 receptor alpha inhibitors, according to Pfizer.1

"Building on these promising findings, we have initiated Phase 3 trials of tilrekimig in atopic dermatitis and asthma, and we are advancing a Phase 2b/3 study in COPD," said Michael Vincent, MD, PhD, chief inflammation and immunology officer at Pfizer.

According to their announcement, Pfizer has dosed patients in 3 phase 3 trials: 2 in atopic dermatitis, including 1 with dupilumab as an active comparator, and 1 in asthma.1

References
  1. Pfizer. Pfizer's tilrekimig shows significant skin clearance in phase 2 atopic dermatitis study. Published October 1, 2026. Accessed October 1, 2026. https://www.businesswire.com/news/home/20260930032966/en/
  2. HCPLive. APEX Part B: zumilokibart achieves primary endpoint in atopic dermatitis. https://www.hcplive.com/view/apex-part-b-zumilokibart-achieves-primary-endpoint-atopic-dermatitis. Published September 30, 2026. Accessed October 1, 2026.
  3. HCPLive. Q&A: precision medicine's next steps in atopic dermatitis, with Peter Lio, MD. https://www.hcplive.com/view/q-a-precision-medicine-next-steps-atopic-dermatitis-peter-lio-md. Published September 10, 2026. Accessed October 1, 2026.

Related to this article

View more